A 26–week, randomized, parallel, treat–to–target trial comparing insulin detemir with NPH insulin as add–on therapy to oral glucose–lowering drugs in insulin–naive people with type 2 diabetes. - Hermansen,K.; Davies,M.; Derezinski,T. (Diabetes Care, 2006)